Combined modality therapy with TRAIL or agonistic death receptor antibodies
Author:
Publisher
Informa UK Limited
Subject
Cancer Research,Pharmacology,Oncology,Molecular Medicine
Link
http://www.tandfonline.com/doi/pdf/10.4161/cbt.11.5.14671
Reference200 articles.
1. Safety and antitumor activity of recombinant soluble Apo2 ligand
2. Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo
3. Identification and characterization of a new member of the TNF family that induces apoptosis
4. Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family
5. Death to the bad guys: Targeting cancer via Apo2L/TRAIL
Cited by 39 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Cellular functions, molecular signalings and therapeutic applications: Translational potential of deubiquitylating enzyme USP9X as a drug target in cancer treatment;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-05
2. Significance of TRAIL/Apo-2 ligand and its death receptors in apoptosis and necroptosis signalling: Implications for cancer-targeted therapeutics;Biochemical Pharmacology;2024-03
3. Production of Soluble Murine TRAILs in Escherichia coli with Zn2+ Supplementation;Protein & Peptide Letters;2022-12
4. Escaping Death: How Cancer Cells and Infected Cells Resist Cell-Mediated Cytotoxicity;Frontiers in Immunology;2022-03-23
5. Unraveling the intracellular cross-talk governing the balance between TNFα mediated survival and apoptosis signaling;2021-09-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3